APLM Stock — Apollomics Inc. Class A: Cash, EV, Pipeline

Share price

$23.42

Market cap

$67.8M

Cash

$3.3M

Enterprise value

$64.5M

Balance sheet

Cash	$3.3M
Debt	$0.0M
Net cash	$3.3M
Enterprise value	$64.5M
Basic shares	2.9M shares
Fully diluted shares	2.4M shares
Fully diluted market cap	$56.2M
Cash per share	$1.13

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading APLM daily closes…

Loading price history…

Pipeline assets

vebreltinib

Stage not disclosed · Active

Target c-Met

Status note Filing identifies vebreltinib as the most advanced / lead product candidate and notes the company has obtained orphan drug designation for it. Phase, indication, target, and modality not stated in the filing excerpts.

Per-asset detail extracted from the 20-F filed 2026-04-24. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	APL-101 Oral Capsules
Lead indication	Solid Tumors
Lead phase	Phase 2
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03175224	Phase 2	Recruiting	Sponsor	Apollomics Inc.	—	Solid Tumors; Advanced Cancer; Renal Cancer	—
NCT04743505	Phase 1/2	Active, not recruiting	Collaborator	Washington University School of Medicine	—	Metastatic Non Small Cell Lung Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Apollomics Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

APLM — Apollomics Inc. Class A

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials